Chemotherapy can save eyes

Article

A direct ophthalmic artery infusion of melphalan for retinoblastoma can enable eyes designated as enucleated to be salvaged, according to a study published in the July 2008 issue of Ophthalmology.

A direct ophthalmic artery infusion of melphalan for retinoblastoma can enable eyes designated as enucleated to be salvaged, according to a study published in the July 2008 issue of Ophthalmology.

David H. Abramson, MD of Memorial Sloan-Kettering Cancer Center, New York and New York-Presbyterian Hospital, Weill-Cornell Medical Center, New York, US and colleagues studied the tolerability and tumouricidal effect of intra-arterial injections of melphalan chemotherapy in paediatric patients (n=10) with retinoblastoma, whose eyes were indicated for enucleation.

In the Phase I/II trial, cannulations were successful 27 times in nine cases, with one patient undergoing six successful attempts. In each treated patient, tumour regression, and reduction of vitreous seeds and subretinal seeds was dramatic.

No transfusions of red blood cells or platelets were required; no severe systemic complications and no toxicity to the cornea, anterior segment, pupil or motility were noted. Three subjects developed conjunctival and lid oedema that resolved without medical intervention; one previously-irradiated eye developed retinal ischaemia; one eye developed a “radiation-like” retinopathy following brachytherapy subsequent to chemotherapy. In eight cases, vision stabilized or improved. Of all treated cases, seven avoided enucleation; the remaining two were enucleated, with no viable tumours identified pathologically.

Given the high success rate of avoiding enucleation and the low level of side effects, the researchers concluded that the direct arterial infusion of melphalan chemotherapy is a viable method of salvaging eyes indicated for enucleation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
Related Content
© 2025 MJH Life Sciences

All rights reserved.